Literature DB >> 7446704

Phorbol myristate acetate: in vivo effects upon neutrophils, platelets, and lung.

J T O'Flaherty, S Cousart, A S Lineberger, E Bond, D A Bass, L R DeChatelet, E S Leake, C E McCall.   

Abstract

Phorbol myristate acetate is a potent aggregator of platelets. It was found that it was similarly potent in aggregating neutrophils and in producing striking thrombocytopenia and neutropenia when infused intravenously into rabbits. Aggregation and cytopenia were further correlated in that both types of responses developed abruptly and persisted for more than 90 minutes. Animals infused with 40 microgram/kg of the phorbol ester exhibited moderately severe respiratory distress. Their respiratory rate doubled shortly after the infusion, and this tachypnea persisted for more than 2 hours. At necroscopic examination, the lungs of these rabbits contained two outstanding abnormalities: numerous foci of alveolar hemorrhage and extensive intravascular accumulations of platelets and neutrophils. Thus, these animals had evidence of increased permeability and potential occlusion of the pulmonary microvasculature. Increased permeability, occlusion of lung blood vessels, or the occurrence of both processes was further indicated in studies on animals pre-infused with the plasma protein marker 125I-albumin: animals infused with the phorbol ester had a significantly increased amount of this label in their lungs in spite of thorough postmortem perfusion of their pulmonary vasculature with saline and fixative. We conclude that phorbol myristate acetate has actions in vivo that resemble those of a variety of other platelet (eg, arachidonic acid) and neutrophil (eg, chemotactic factors) aggregating agents that cause cytopenia and lung dysfunction. However, compared with these other agents, the phorbol ester produces respiratory distress of intermediate severity and greater duration. The drug, therefore, induces a syndrome that more closely resembles that seen in a variety of clinical and experimental conditions that associate shocklike states with cytopenia and lung dysfunction. It may serve as a useful tool in the study of the pathophysiology of these states as well as in those produced by other aggregating agents.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7446704      PMCID: PMC1903583     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  28 in total

1.  An endoperoxide aggregator (Lass), formed in platelets in response to thrombotic stimuli: purification, identification and unique biological significance.

Authors:  A L Willis; F M Vane; D C Kuhn; C G Scott; M Petrin
Journal:  Prostaglandins       Date:  1974-12-25

2.  Isolation of a chemical trigger for thrombosis.

Authors:  A L Willis
Journal:  Prostaglandins       Date:  1974-01-10

3.  A low-viscosity epoxy resin embedding medium for electron microscopy.

Authors:  A R Spurr
Journal:  J Ultrastruct Res       Date:  1969-01

4.  The nonspecific pulmonary inflammatory reactions leading to respiratory failure after shock, gangrene, and sepsis.

Authors:  G H Clowes; W Zuschneid; S Dragacevic; M Turner
Journal:  J Trauma       Date:  1968-09

5.  Selective labilization of specific granules in polymorphonuclear leukocytes by phorbol myristate acetate.

Authors:  J G White; R D Estensen
Journal:  Am J Pathol       Date:  1974-04       Impact factor: 4.307

6.  Cytochemical electron microscopic studies of the action of phorbol myristate acetate on platelets.

Authors:  J G White; R D Estensen
Journal:  Am J Pathol       Date:  1974-03       Impact factor: 4.307

7.  Ultrastructural features on the platelet response to phorbol myristate acetate.

Authors:  R D Estensen; J G White
Journal:  Am J Pathol       Date:  1974-03       Impact factor: 4.307

8.  Arachidonic acid causes sudden death in rabbits.

Authors:  M J Silver; W Hoch; J J Kocsis; C M Ingerman; J B Smith
Journal:  Science       Date:  1974-03-15       Impact factor: 47.728

9.  Investigation of the release reaction in platelets exposed to phorbol myristate acetate.

Authors:  J G White; G H Rao; R D Estensen
Journal:  Am J Pathol       Date:  1974-05       Impact factor: 4.307

10.  The tumor-promoter phorbol ester (12-O-tetradecanoyl-phorbol-13-acetate), a potent aggregating agent for blood platelets.

Authors:  M B Zucker; W Troll; S Belman
Journal:  J Cell Biol       Date:  1974-02       Impact factor: 10.539

View more
  18 in total

1.  12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced increase in depressed white blood cell counts in patients treated with cytotoxic cancer chemotherapeutic drugs.

Authors:  Z T Han; Y K Tong; L M He; Y Zhang; J Z Sun; T Y Wang; H Zhang; Y L Cui; H L Newmark; A H Conney; R L Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

2.  Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity.

Authors:  Z T Han; X X Zhu; R Y Yang; J Z Sun; G F Tian; X J Liu; G S Cao; H L Newmark; A H Conney; R L Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

Review 3.  Biology and biochemistry of platelet-activating factor.

Authors:  J T O'Flaherty; R L Wykle
Journal:  Clin Rev Allergy       Date:  1983-09

4.  Pulmonary injury induced by phorbol myristate acetate following intravenous administration in rabbits. Acute respiratory distress followed by pulmonary interstitial pneumonitis and pulmonary fibrosis.

Authors:  C E McCall; R G Taylor; S L Cousart; R D Woodruff; J C Lewis; J T O'Flaherty
Journal:  Am J Pathol       Date:  1983-05       Impact factor: 4.307

5.  The protein kinase C activator phorbol myristate acetate decreases brain edema by aquaporin 4 downregulation after middle cerebral artery occlusion in the rat.

Authors:  Giovanna Fazzina; Angela M Amorini; Christina R Marmarou; Shinji Fukui; Kenji Okuno; Jana G Dunbar; Renee Glisson; Anthony Marmarou; Andrea Kleindienst
Journal:  J Neurotrauma       Date:  2010-02       Impact factor: 5.269

6.  Modification of hepatic protein kinase C with phorbol myristate acetate and staurosporine alters hemodynamics in the perfused rat liver.

Authors:  H Inaba; M Araki; T Numai; T Mizuguchi
Journal:  J Anesth       Date:  1993-01       Impact factor: 2.078

7.  Ether lipid content and fatty acid distribution in rabbit polymorphonuclear neutrophil phospholipids.

Authors:  H W Mueller; J T O'Flaherty; R L Wykle
Journal:  Lipids       Date:  1982-02       Impact factor: 1.880

8.  Neutrophil-independence of the initiation of colonic injury. Comparison of results from three models of experimental colitis in the rat.

Authors:  M G Buell; M C Berin
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

9.  Neutropenia induced by systemic infusion of 5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid: correlation with its in vitro effects upon neutrophils.

Authors:  J T O'Flaherty; M J Thomas; S L Cousart; W L Salzer; C E McCall
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

10.  Synergistic effect of heparin and chemotactic factor on polymorphonuclear leukocyte aggregation and degranulation.

Authors:  M S Cairo; J Allen; C Higgins; R L Baehner; L A Boxer
Journal:  Am J Pathol       Date:  1983-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.